About Infertility Drugs
Infertility can be defined as an inability of a person to reproduce through natural means. Infertility can occur in any of the two genders, i.e., male and female.
Technavio’s analysts forecast the global infertility drugs market to grow at a CAGR of 4.67% during the period 2018-2022.
Covered in this report
The report covers the present scenario and the growth prospects of the global infertility drugs market for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Infertility Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer
• Ferring
• Merck
• Novartis
Market driver
• Growing lifestyle diseases
• For a full, detailed list, view our report
Market challenge
• Rising inclination toward other modes of treatment for infertility
• For a full, detailed list, view our report
Market trend
• Raising awareness regarding infertility in couples
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Introduction
• Diagnosis and treatment
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing
• Market size and forecast
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE ANALYSIS
PART 09: MARKET SEGMENTATION BY THERAPY
• Segmentation by therapy
• Comparison by therapy
• Global hormone-based therapy market
• Global others market
• Market opportunity by therapy
PART 10: MARKET SEGMENTATION BY GENDER
• Segmentation by gender
• Global female infertility drugs market
• Global male infertility drugs market
PART 11: CUSTOMER LANDSCAPE
PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Infertility drugs market in Americas
• Infertility drugs market in EMEA
• Infertility drugs market in APAC
• Market opportunity
PART 13: DECISION FRAMEWORK
PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 15: MARKET TRENDS
• Raising awareness regarding infertility in couples
• Growing online retail sales of drugs
PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 17: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer
• Ferring
• Merck
• Novartis
PART 18: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Definition of infertility in different genders
Exhibit 02: Fertility rates, 2015
Exhibit 03: Parent market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition: Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global infertility drugs market 2017-2022 ($ millions)
Exhibit 10: Major factors affecting the global infertility drugs market 2017
Exhibit 11: Global infertility drugs market: Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 12: Five forces analysis 2017
Exhibit 13: Five forces analysis 2022
Exhibit 14: Bargaining power of buyers
Exhibit 15: Bargaining power of suppliers
Exhibit 16: Threat of new entrants
Exhibit 17: Threat of substitutes
Exhibit 18: Threat of rivalry
Exhibit 19: Market condition: Five forces 2017
Exhibit 20: Pipeline analysis by development phase
Exhibit 21: Key clinical trials
Exhibit 22: Segmentation of global infertility drugs market by therapy 2017-2022 (%)
Exhibit 23: Comparison by therapy
Exhibit 24: Global hormone-based therapy market 2017-2022 ($ millions)
Exhibit 25: Hormonal therapy for infertility
Exhibit 26: Global hormone-based therapy market: Y0Y growth 2018-2022 (%)
Exhibit 27: Global others market 2017-2022 ($ millions)
Exhibit 28: Global others market: YoY growth 2018-2022 (%)
Exhibit 29: Market opportunity by therapy
Exhibit 30: Segmentation of global infertility drugs market by gender 2017
Exhibit 31: Customer landscape
Exhibit 32: Global infertility drugs market share by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Infertility drugs market in Americas 2017-2022 ($ millions)
Exhibit 35: Infertility drugs market in Americas: YoY growth 2018-2022 (%)
Exhibit 36: Fertility rate in top three countries in Americas 1960-2015
Exhibit 37: Top three countries in Americas
Exhibit 38: Infertility drugs market in EMEA 2017-2022 ($ millions)
Exhibit 39: Infertility drugs market in EMEA: YoY growth 2018-2022 (%)
Exhibit 40: Fertility rate in top three countries in EMEA 1960-2015
Exhibit 41: Top three countries in EMEA
Exhibit 42: Infertility drugs market in APAC 2017-2022 ($ millions)
Exhibit 43: Infertility drugs market in APAC: YoY growth 2018-2022 (%)
Exhibit 44: Fertility rate in top three countries in APAC 1960-2015
Exhibit 45: Top three countries in APAC
Exhibit 46: Market opportunity
Exhibit 47: Pregnancy complications in diabetic women after embryo implantation
Exhibit 48: Diabetes effect on men fertility
Exhibit 49: Global fertility rate
Exhibit 50: Demographic and economic snapshot of India and China
Exhibit 51: Non-therapeutic mode of infertility treatment
Exhibit 52: Side effects of medications used in infertility treatment
Exhibit 53: Vendor landscape
Exhibit 54: Landscape disruption
Exhibit 55: Vendors covered
Exhibit 56: Vendor classification
Exhibit 57: Market positioning of vendors
Exhibit 58: Bayer: Vendor overview
Exhibit 59: Bayer: Business segments
Exhibit 60: Bayer: Organizational developments
Exhibit 61: Bayer: Geographic focus
Exhibit 62: Bayer: Segment focus
Exhibit 63: Bayer: Key offerings
Exhibit 64: Ferring: Vendor overview
Exhibit 65: Ferring: Business segments
Exhibit 66: Ferring: Organizational developments
Exhibit 67: Ferring: Geographic focus
Exhibit 68: Ferring: Segment focus
Exhibit 69: Ferring: Key offerings
Exhibit 70: Merck: Vendor overview
Exhibit 71: Merck: Business segments
Exhibit 72: Merck: Organizational developments
Exhibit 73: Merck: Geographic focus
Exhibit 74: Merck: Segment focus
Exhibit 75: Merck: Key offerings
Exhibit 76: Novartis: Vendor overview
Exhibit 77: Novartis: Business segments
Exhibit 78: Novartis: Organizational developments
Exhibit 79: Novartis: Geographic focus
Exhibit 80: Novartis: Segment focus
Exhibit 81: Novartis: Key offerings
